Anavex Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Dec '24 Dec 31, 2024	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	2019 - 2015
Net Income	-46.49	-43	-47.51	-47.98	-37.91	-26.28	Upgrade
Stock-Based Compensation	9.21	9.44	16.37	18.38	8.23	4.88	Upgrade
Other Operating Activities	-	-	0.85	-	-	-	Upgrade
Change in Accounts Payable	0.28	5.31	0.5	-0.91	0.75	0.47	Upgrade
Change in Unearned Revenue	-0.09	-0.08	0.47	-	0.44	-	Upgrade
Change in Other Net Operating Assets	1.48	-2.48	1.54	6.28	-1.9	-0.35	Upgrade
Operating Cash Flow	-35.61	-30.81	-27.79	-24.24	-30.38	-21.29	Upgrade
Issuance of Common Stock	12.62	11.98	29.65	22	158.79	28.75	Upgrade
Other Financing Activities	-	-	-	-0.71	-5.55	-0.4	Upgrade
Financing Cash Flow	12.62	11.98	29.65	21.29	153.24	28.35	Upgrade
Net Cash Flow	-22.99	-18.84	1.87	-2.95	122.86	7.06	Upgrade
Free Cash Flow	-35.61	-30.81	-27.79	-24.24	-30.38	-21.29	Upgrade
Free Cash Flow Per Share	-0.42	-0.37	-0.35	-0.32	-0.44	-0.37	Upgrade
Cash Income Tax Paid	0.3	0.3	0.14	0.33	0.14	0.02	Upgrade
Levered Free Cash Flow	-22.24	-19.43	-14.27	-6.03	-15.9	-11.7	Upgrade
Unlevered Free Cash Flow	-22.24	-19.43	-14.27	-6.03	-15.9	-11.7	Upgrade
Change in Net Working Capital	-1.67	-2.75	-2.51	-5.38	0.72	-0.12	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.